Mifepristone DANGER: Hidden Risks Exposed!

Senator Josh Hawley just introduced a bold bill to yank FDA approval for the dangerous chemical abortion drug mifepristone, shielding women from its hidden risks after years of regulatory neglect.

Story Highlights

Hawley unveils Safeguarding Women from Chemical Abortion Act to revoke FDA approval of mifepristone and allow harmed women to sue manufacturers like Danco Laboratories.
Press conference on March 11, 2026, features wrenching testimonies from women injured by the drug and pro-life leaders demanding action.
EPPC research reveals complications 22 times higher than FDA labels, exposing corporate profiteering at women’s expense.
Companion bill forthcoming in House from Rep. Diana Harshbarger amid Trump administration’s ongoing FDA review.

Bill Targets FDA Overreach on Mifepristone

U.S. Senator Josh Hawley (R-Mo.) introduced the Safeguarding Women from Chemical Abortion Act on March 11, 2026. The legislation withdraws FDA approval of mifepristone specifically for abortion use. It classifies distribution of the drug for pregnancy termination as a violation of the Federal Food, Drug, and Cosmetic Act. Hawley unveiled the bill at a Capitol press conference attended by women harmed by chemical abortions and pro-life advocates. This measure empowers injured women with a private right of action to sue manufacturers directly. Danco Laboratories, the primary producer, faces accountability for billions in profits from the drug.

Press Conference Spotlights Real Harms to Women

Women shared harrowing testimonies at the March 11 event, detailing severe complications from mifepristone, the first drug in the two-step chemical abortion regimen. Pro-life leaders joined Hawley to urge Congress to override FDA inaction. Concerned Women for America Legislative Action Committee commended the bill as a necessary step against the inherently dangerous drug. Hawley declared the science clear: mifepristone poses unacceptable risks prone to abuse, especially via mail-order under Biden-era rules. These stories underscore the human cost ignored by regulators and Big Pharma.

Historical FDA Failures and Post-Dobbs Pushback

The FDA approved mifepristone in 2000 under President Clinton for early abortions. Biden officials later eased restrictions, enabling telehealth and mail-order access despite safety concerns. The 2024 Supreme Court dismissed a challenge on standing grounds, preserving availability without addressing merits. In Trump’s second term, FDA Commissioner Marty Makary pledged a review, but progress stalls with a one-year timeline estimated. Hawley’s prior May 2025 bill focused on safeguards; this version escalates by revoking approval outright. EPPC data shows real-world side effects 22 times the FDA label, fueling demands for congressional intervention. Medication abortions comprised 63% of U.S. cases in 2023 per Guttmacher Institute.

Key Players Challenging the Status Quo

Hawley leads as Senate sponsor, backed by Rep. Diana Harshbarger for the House companion. Pro-life groups like CWALAC, Ethics and Public Policy Center, and Restoration of America Foundation rally support, citing unregulated mail-order fueling over 500 daily abortions. Danco Laboratories profits immensely while women suffer. Guttmacher Institute tracks high usage but downplays risks. Trump administration paused state lawsuits for FDA review and approved generics, drawing criticism for insufficient action. Hawley’s bill tests GOP resolve amid low odds of national bans due to Trump’s veto pledge.

Potential Impacts and Path Forward

Passage could accelerate FDA scrutiny, enable lawsuits against manufacturers, and curb medication abortions dominating post-Dobbs landscape with 1,038,100 clinician-provided cases in 2024. Women gain recourse for harms; providers shift from telehealth models. Economically, Danco’s revenue takes a hit. Politically, it highlights tensions in Republican Congress over family values and limited government overriding rogue agencies. No committee action yet; faces uphill battle but amplifies calls for protecting women and unborn amid regulatory capture. Limited passage data available as bill freshly introduced.